PeptideCompareOS-01 — EU research guide.
OS-01 (Peptide 14) is a senotherapeutic peptide developed by OneSkin, used topically to reduce cellular senescence in skin — a peptide marketed specifically around a measured ‘skin biological age’ effect.
What is OS-01?
OS-01 is designed to reduce the burden of senescent (‘zombie’) cells in skin tissue, which accumulate with age and secrete inflammatory signals (the SASP). In published trials it improved barrier function, hydration and some wrinkle and texture measures; the reported lowering of skin DNA-methylation age comes from ex vivo skin biopsies in a 2020 preprint, not from those trials.
What does the research show?
Two small, double-blind 12-week trials — a vehicle-controlled split-face study and a body-lotion pilot study measuring systemic inflammation markers — reported improvements in skin barrier and appearance measures. Authors are linked to the manufacturer, and the pilot used a commercial moisturiser as control. It is sold exclusively as a cosmetic ingredient by OneSkin; it is not developed or studied as an injectable or oral longevity compound, despite informal community interest in doing so.
EU legal status
Regulated as a cosmetic ingredient, not a medicine — sold within finished skincare products, not as a standalone RUO peptide. Any injectable or oral “OS-01” sold by research-peptide vendors falls outside its studied and intended use.
Molecular information
Pharmacokinetics
Potency retained over time
Each line is one storage condition: it starts at 100% and falls as potency is lost. Above the dashed 80% line the material is considered reliable — hover for exact values.
⚠ Modelled per compound from molecular structure — chain length, cyclisation, oxidation- and deamidation-prone residues and light sensitivity. Indicative only, not lab-measured per batch.
Longevity & skin-aging compounds across EU suppliers
COA-verified EU vendors · Updated monthly
References
- Safety study of Peptide 14: no toxicity in human skin cells and skin equivalents, negative genotoxicity assays and no visible reactions in a patch test on 54 participants. It supports topical tolerability only and also gives the published sequence. Zonari A, Brace LE, Alencar-Silva T, Porto WF, Foyt D, Guiang M, Ochoa Cruz EA, Franco OL, Oliveira CR, Boroni M, Carvalho JL. In vitro and in vivo toxicity assessment of the senotherapeutic Peptide 14. Toxicol Rep. 2022;9:1632-1638. DOI
- Small 12-week split-face trial (22 women) from the same research group as the 2025 paper, reporting barrier, wrinkle and radiance measures with a vehicle control. Cosmetic endpoints only; numbers were read from summaries of the paper, so check the abstract. Zonari A, et al. Double-blind, vehicle-controlled clinical investigation of peptide OS-01 for skin rejuvenation. J Cosmet Dermatol. 2024;23(6). DOIPubMed 38400612
- Randomised 12-week pilot of an OS-01 body lotion against a commercial moisturiser. Multiple authors have commercial ties to the manufacturer, the control was not a matched vehicle and the sample was small, so the blood-marker and GlycanAge findings are preliminary. Zonari A, Brace LE, Buhrer LB, Harder NHO, Harker C, Aronson AB, Tse CN, Oliveira CR, Boroni M, Carvalho JL. OS-01 peptide topical formulation improves skin barrier function and reduces systemic inflammation markers: a pilot 12-week clinical trial. J Cosmet Dermatol. 2025;24(4). DOIPubMed 40193112
- Laboratory study on human immune cells (in vitro) reporting a shift toward anti-inflammatory signals. It is mechanistic cell data and does not show the effect in people. Alencar-Silva T, de Barcelos SM, Silva-Carvalho A, et al. Senotherapeutic Peptide 14 suppresses Th1 and M1 human T cell and monocyte subsets in vitro. Cells. 2024;13(10):813. DOI
- 2020 preprint, not peer reviewed as far as could be verified: ex vivo human skin biopsies (donors aged 35, 55 and 79) in which the peptide lowered DNA methylation age, by about 2.6 years in the 79-year-old sample after five days. This is the source of the skin DNA-methylation claim; it is tissue data, not a clinical trial. Senotherapeutic peptide reduces skin biological age and improves skin health markers. bioRxiv preprint (not peer reviewed). 2020. DOI